Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA recommends 4SC's resminostat for orphan designation

This article was originally published in Scrip

Executive Summary

The European Medicines Agency (EMA) has adopted a positive opinion for 4SC's resminostat to be given orphan drug designation for the treatment of hepatocellular carcinoma, which was a second piece of recent good news for the company, as they were able to present positive data for the drug in June (scripintelligence.com, scripintelligence.com, 23 June 2011). 4SC now has lots riding on resminostat's success, as its share price plunged by a third last month when its lead candidate, vidofludimus, failed to meet its primary endpoint (scripintelligence.com scripintelligence.com, 8 June 2011).

You may also be interested in...



Almirall launches Constella in six European markets

Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.

Dermira raises $35m in series B

Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.

Clovis ups public offering to $240m

Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.

Topics

Related Companies

UsernamePublicRestriction

Register

SC013867

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel